Maxime Dely on The vital Role of Plasma in Immune-Deficient Patients
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”Immunoglobulins: when plasma becomes a vital treatment for immune-deficient patients
Intravenous and subcutaneous immunoglobulins (IVIg, SCIg), produced exclusively from plasma donations, are life-saving medicines.
They replace or support the immune system in a wide range of conditions.
Main indications
- Primary immunodeficiencies (rare and severe congenital disorders)
- Secondary immunodeficiencies (after transplantation, chemotherapy, uncontrolled HIV, etc.)
- Autoimmune and neurological diseases (Guillain-Barré syndrome, myasthenia gravis, Kawasaki disease, immune thrombocytopenia, and more)
Worldwide
Today, millions of patients rely on immunoglobulin therapy every year.
Currently, the global demand is growing steadily (+5–7% annually), driven by broader indications and aging populations.
Unfortunately, there is no synthetic or recombinant alternative today — plasma is the only source.
Immunoglobulins are not only life-saving but also critical for maintaining quality of life in chronic patients.
Behind every infusion of immunoglobulins, there are thousands of plasma donations, transformed into precious medicines.
How can we raise more awareness about the growing importance of plasma-derived immunoglobulins, as global demand keeps rising?”
Stay updated on all scientific advances in the field of transfusion medicine with Hemostasis Today.
-
May 24, 2026, 13:10Thomas Pincez: Emerging Challenges in Sickle Cell Disease Gene Therapy and Cancer Risk
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management